RankAlpha logo
Back to Rankings

CRDF

Cardiff OncologyC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Cardiff's Phase 2 response-rate signal and FDA-aligned Phase 3 design support upside if it secures financing on acceptable terms and confirms benefit in a registrational trial [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm). The September Nerviano settlement also addressed a prior license dispute, although the amended agreement carries milestone and other payment obligations (https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/form8-k.htm).
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
No October 29 Q3 company earnings release or earnings 8-K was found in the checked company release and SEC filing lists; reported Q3 revenue, EPS, guidance, and consensus surprise are unavailable (https://investors.cardiffoncology.com/news-events/press-releases; https://investors.cardiffoncology.com/financial-information/sec-filings).
Momentum
91
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.85 · Bull $1.50 · Bear $0.45Analysis 2026-10-30; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-30 • Vendor: Data Vendor v1
Scores
As of 2026-10-30 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-30 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-30

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-30. Definitions

Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $5.14
Why
Momentum91 · Δ7d -
Value41 · Δ7d +0.0
Sentiment60 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Confirming evidence

  • • Sentiment remains the lead driver in the composite.

Contradictions & invalidation

  • • No October 29 Q3 company earnings release or earnings 8-K was found in the checked company release and SEC filing lists; reported Q3 revenue, EPS, guidance, and consensus surprise are unavailable (https://investors.cardiffoncology.com/news-events/press-releases; https://investors.cardiffoncology.com/financial-information/sec-filings).
  • • Phase 2 progression-free-survival estimates had wide confidence intervals; later-stage efficacy, safety, enrollment, and regulatory success are not assured [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm).
  • • The Phase 3 start depends on new capital.

Catalyst clock

2026-11-30

Confirm Q3 results and updated cash runway

Lead driver: Sentiment · See AI snapshot
Momentum
91
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.2
Sentiment
60
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade C. Momentum 90.6 / Value 40.6 / Sentiment 60.0

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-30. Scenario method

B+
Bull case
25%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-10-30 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-10-30 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-10-30 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-30
Market Cap
$69.21M
Beta
1.33
Shares Out
77.8M
P/E (TTM) · Derived
-1.3
P/S (TTM)
381.84
P/FCF (TTM) · Derived
-1.48
Rev YoY
-14.0%
EPS YoY
-35.6%
Gross Margin
-75.2%
Op Margin
-8320.1%
Net Debt
-$57.47M
Current Ratio
3.30
As of 2026-10-30 • Updated nightlySource: Internal modelMethods & Data